phenylalanine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2144 | 63-91-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal growth restriction | 89.70 | 64.17 | 15 | 110 | 7538 | 63481359 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:27027 | trace elements |
| CHEBI has role | CHEBI:50733 | Dietary Supplement |
| CHEBI has role | CHEBI:63332 | alkaline phosphatase inhibitors |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
| CHEBI has role | CHEBI:76924 | plant metabolites |
| CHEBI has role | CHEBI:76967 | human xenobiotic metabolites |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:84735 | algal metabolites |
| CHEBI has role | CHEBI:83056 | Daphnia magna metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Classical phenylketonuria | contraindication | 7573000 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Sarcoidosis | contraindication | 31541009 | DOID:11335 |
| End stage renal disease | contraindication | 46177005 | DOID:784 |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Ventricular fibrillation | contraindication | 71908006 | |
| Hypercalciuria | contraindication | 71938000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.27 | acidic |
| pKa2 | 9.25 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Large neutral amino acids transporter small subunit 1 | Transporter | IC50 | 4.16 | CHEMBL | |||||
| Probable G-protein coupled receptor 139 | GPCR | AGONIST | IC50 | 4.51 | IUPHAR | ||||
| Intestinal-type alkaline phosphatase | Enzyme | IC50 | 4 | CHEMBL | |||||
| E3 ubiquitin-protein ligase XIAP | Unclassified | IC50 | 4.10 | CHEMBL | |||||
| Voltage-dependent calcium channel subunit alpha-2/delta-1 | Ion channel | Ki | 6.01 | CHEMBL | |||||
| L-type amino acid transporter 1 | Transporter | Ki | 4.26 | CHEMBL | |||||
| Intestinal alkaline phosphatase | Enzyme | IC50 | 4.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018673 | VUID |
| N0000146984 | NUI |
| 4018673 | VANDF |
| C0031453 | UMLSCUI |
| CHEBI:28044 | CHEBI |
| PHE | PDB_CHEM_ID |
| CHEMBL301523 | ChEMBL_ID |
| DB00120 | DRUGBANK_ID |
| D010649 | MESH_DESCRIPTOR_UI |
| 6140 | PUBCHEM_CID |
| 6168 | INN_ID |
| 3313 | IUPHAR_LIGAND_ID |
| 47E5O17Y3R | UNII |
| 8156 | RXNORM |
| 40037 | MMSL |
| NOCODE | MMSL |
| 003542 | NDDF |
| 421626005 | SNOMEDCT_US |
| 63004003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ProcalAmine | HUMAN PRESCRIPTION DRUG LABEL | 22 | 0264-1915 | INJECTION | 0.17 g | INTRAVENOUS | NDA | 24 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.48 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.48 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.48 g | INTRAVENOUS | NDA | 23 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3200 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3205 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
| Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 1.04 g | INTRAVENOUS | ANDA | 20 sections |
| FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9010 | INJECTION, SOLUTION | 0.56 g | INTRAVENOUS | NDA | 24 sections |
| FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9011 | INJECTION, SOLUTION | 0.56 g | INTRAVENOUS | NDA | 24 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 0.48 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.29 g | INTRAVENOUS | NDA | 23 sections |
| HepatAmine | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9371 | INJECTION, SOLUTION | 0.10 g | INTRAVENOUS | NDA | 23 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 448 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 336 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 336 mg | INTRAVENOUS | NDA | 21 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |
| CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 448 mg | INTRAVENOUS | NDA | 20 sections |